Good
Mostly Aligned
Patient Risk:
Low
Summary
Core product description (hormonal/levonorgestrel IUS), and contraceptive indication are supported by the provided label excerpts. Manufacturer/ownership and “same drug class as other levonorgestrel IUD brands” are not supported by the provided prescribing information excerpts, resulting in minor-to-moderate unsupported content.
Category Scores
Accurate Statements
Liletta is a hormonal intrauterine device (IUD).
Supported: Label describes LILETTA as a levonorgestrel-releasing intrauterine system (IUS) and includes progestogenic/local effects (Sections 1, 12.2).
Liletta uses the same drug class as other levonorgestrel IUD brands.
Partially supported only at the product-class level: Label states LILETTA contains levonorgestrel (52 mg) and is an LNG-releasing IUS (Sections 1, 12.1/12.2). However, label excerpts provided do not explicitly compare it to “other levonorgestrel IUD brands” as a class-identity statement.
Liletta is a levonorgestrel IUD.
Supported: Label identifies LILETTA as levonorgestrel-releasing intrauterine system and active ingredient levonorgestrel (Sections 1, Drug/Active ingredient excerpts, 12).
Liletta is used for birth control.
Supported: Indication for prevention of pregnancy (Section 1 INDICATIONS AND USAGE).
Unsupported Statements
Liletta is made by Allergan Aesthetics, which is part of AbbVie.
Not supported by the provided prescribing information excerpts. No manufacturer/ownership statement is included in the label text provided.
In the U.S., the company listed as the manufacturer is Allergan Aesthetics (AbbVie).
Not supported by the provided prescribing information excerpts. No U.S. manufacturer/company listing is included in the excerpts provided.
Liletta uses the same drug class as other levonorgestrel IUD brands.
The excerpts provided confirm LILETTA is a levonorgestrel-releasing intrauterine system, but do not explicitly state equivalence to the “same drug class as other levonorgestrel IUD brands.”
Contradictions
Important Omissions
If the question is about approval status/indications, the label also specifies duration for contraception (up to 8 years) and treatment of heavy menstrual bleeding (up to 5 years), which were not mentioned by the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported content relates to manufacturer/ownership and broad class comparison, which are not directly prescribing/safety directions in the provided excerpts. Indication and product description are consistent with the label. No dosing, contraindications, warnings, or administration instructions were misstated.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Manufacturer/ownership and class-comparison claims are not supported by the provided label excerpts.
Suggested Improvement
Remove or qualify statements about Allergan Aesthetics/AbbVie ownership and the “same drug class as other brands” comparison unless the provided label text explicitly states these points. If describing use, include label-supported details such as contraception duration (up to 8 years) when relevant.